On July 27, 2023, Aeglea BioTherapeutics, Inc. entered into and closed the transactions contemplated by that certain Asset Purchase Agreement (the Purchase Agreement) with Immedica Pharma AB, a limited company (Aktiebolag) organized and existing under the laws of Sweden ("Immedica"). Subject to the terms and conditions of the Purchase Agreement, at the closing of the transactions (the " Closing") contemplated by the Purchase Agreement (the Asset Purchase), Immedica purchased from the Company its assets related to its research, development and manufacturing program for pegzilarginase for the treatment of Arginase-1 Deficiency as well as other therapeutic, prophylactic, palliative and diagnostic uses (the " Program," and any pharmaceutical product containing, incorporating or comprising pegzilarginase, the Product") for an initial payment in cash of $15,000,000 due at Closing and up to $100,000,000 after the Closing (the Milestone Events), payable upon the achievement of certain milestones based on sale and regulatory approvals related to the Product (the Milestone Events). The Purchase Agreement contains customary representations, warranties and covenants of the parties.

The Company, on the one hand, and Immedica, on the other hand, have agreed to indemnify each other from and against losses the respective parties may incur arising out of breaches of the other party's representations, warranties and covenants contained in the Purchase Agreement and for certain other liabilities, subject to specified survival limitations and other customary exceptions and limitations. Pursuant to the Purchase Agreement, Immedica has the right to set off indemnifiable amounts, subject to certain limitations, against any Milestone Payment that may become payable.